Physiomics PLC Contract Award
31 8월 2023 - 3:00PM
RNS Non-Regulatory
TIDMPYC
Physiomics PLC
31 August 2023
31 August 2023
Physiomics plc
("Physiomics") or ("the Company")
Contract award
Physiomics plc (AIM: PYC), a leading mathematical modelling
company, supporting development of oncology drugs and personalised
medicine solutions, is pleased to announce that it has been awarded
a further contract by existing client Merck KGaA that it expects to
be completed over the next three months. The project will involve
pre-clinical and clinical modelling and simulation of anti-cancer
regimens involving combinations of DNA damage/ repair agents and
follows on from previous projects commissioned by Merck KGaA.
Physiomics CEO, Dr Jim Millen, commented: "We are pleased that
this longstanding client has once again chosen Physiomics as a
partner for outsourced modelling. We look forward to the
possibility of further projects with Merck during the current
financial year."
Enquiries:
Physiomics plc
Dr Jim Millen, CEO
+44 (0)1865 784 980
Hybridan LLP (broker)
Claire Louise Noyce
+44 (0) 203 764 2341
Strand Hanson Ltd (NOMAD)
James Dance & James Bellman
+44 (0)20 7409 3494
Notes to Editor
About Physiomics
Physiomics plc combines cutting edge PKPD and QSP modelling
techniques with cancer biology expertise, to help biotech and
pharma companies streamline their drug development journeys. Our
approach is to derive insight from all relevant data in order to
de-risk decision making and optimise design of pre-clinical and
clinical studies. Through use of bespoke models and our proprietary
Virtual Tumour technology, the Physiomics team has informed the
development of over 100 projects, over 40 targets and 70 drugs.
Clients include Merck KGaA, Astellas, Bicycle Therapeutics, Numab
Therapeutics & CRUK.
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRAWPUUURUPWGAU
(END) Dow Jones Newswires
August 31, 2023 02:00 ET (06:00 GMT)
Physiomics (LSE:PYC)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024
Physiomics (LSE:PYC)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024